The economics that good ideas deserve

There is a pattern so common in healthcare that it has its own vocabulary. The pilot. The conference presentation. The follow-on pilot. The evaluation committee. The procurement freeze. The quietly shelved project. Something that demonstrably works stops working the moment it has to become a business. And the people who built it, and the people who funded it, find themselves holding evidence that no one seems to be able to act on. This is the dominant failure mode in healthcare innovation. Not the science. Not the technology. The economics around it, which were never designed. ## Why procurement is where good ideas go to die Across health systems internationally, facility-level procurement decisions are governed by three things: cost, compliance, and vendor credibility. Not by frameworks capable of evaluating clinical effectiveness, cost-utility, or long-term fit. Most procurement officers are not equipped with health technology assessment methodologies. Most digital health solutions enter hospitals and clinic networks without the evidence burden that would expose their real-world performance. CE marking and ISO certification create regulatory legitimacy without requiring clinical trial data. The result is that the most consequential adoption decisions in healthcare are being made by processes designed for buying equipment, not governing the introduction of clinical-grade technology. This is not a criticism of procurement teams. It is a description of a structural gap. The procurement pathway was not built for what is now being asked of it. For a founder, this has a direct implication. Your clinical evidence, however rigorous, does not automatically translate into a purchasing decision. The committee evaluating your product is not running the same analysis your clinical advisors ran. They are optimising for total cost of ownership, integration risk, vendor track record, and contract flexibility. Understanding that is not a commercial inconvenience. It is the work. The EU's HTA Regulation has begun to create conditions for joint clinical assessment and outcome-based market access at European level. But implementation at facility level remains largely disconnected from those frameworks. Procurement at the hospital or clinic follows local acquisition logic. Regulation helps outcome-based solutions enter markets. It does not yet ensure they are procured on those terms. For an investor, this means pilot traction is a weak signal of commercial durability. The question is not whether the product works. The question is whether anyone has mapped a clear path from clinical validation to procurement approval to contract renewal to spread across a health system. Those are four separate problems, and most pitch decks treat them as one. ## The deeper problem: value goes one place, cost lands somewhere else Beneath the procurement challenge sits something harder to fix. Digital health creates value in ways that existing financial models were not designed to measure or attribute. Clinical outcomes improve over time, not at the point of intervention. Efficiency gains accrue across care pathways, not within a single department's budget. Coordination costs fall across organisations that do not share a P&L. The value is real. The financial architecture for capturing and attributing it has not caught up. The consequence is a persistent structural mismatch. The party bearing the cost of implementation is rarely the party capturing the benefit. A health-tech product that reduces readmissions generates value for a payer. If it is sold to a hospital, the financial incentive to buy is attenuated. A digital triage tool that reduces emergency department congestion benefits the system. The department purchasing it sees a cost line with a diffuse return. This is not a failure of vision on anyone's part. It is a design problem. The financial architecture that governs health procurement was built for a world where value is transactional, immediate, and contained within organisational boundaries. Digital health is none of those things. Outcome-based payment models and value-based procurement frameworks are beginning to address it in some markets. But the gap between regulatory intent and procurement reality remains wide. A founder who does not understand where value actually accrues in their target market, and who it accrues to, will build a pricing model that works on a whiteboard and stalls in a budget meeting. ## What durable economics actually looks like The ventures that reach scale in healthcare share a set of economic characteristics that are worth naming. They have designed for the procurement pathway, not just the clinical proof. They know who in the target organisation has budget authority, what evaluation criteria that person applies, and what the contract and renewal cycle looks like. They have worked backwards from that process before committing to a go-to-market motion. They have mapped the value flow with specificity. They know who captures the economic benefit of their product, and they have structured commercial terms that align the buyer's incentive with that benefit. Where the buyer and the beneficiary are different entities, they have a theory of how to bridge that gap, not a plan to figure it out later. They have reimbursement logic that is specific to their markets. Not "we will pursue reimbursement" as a future milestone, but a concrete view of which code, which pathway, and which evidence dossier is required to get there. In markets where reimbursement does not yet exist, they are operating at a margin that does not depend on it arriving on schedule. They have partnership structures that reflect the real economics of care delivery. The health-tech companies that reach institutional scale are rarely doing so alone. They have negotiated with payers, providers, or distributors in ways that share risk and reward in proportion to where value is created, because unilateral value capture in a system with this many interdependencies is a fragile position. None of this is formulaic. Healthcare markets differ enough that there is no standard playbook. What is consistent is the discipline: someone did the economic design work before the commercial motion began. ## The questions most investment evaluations skip The pattern of venture-backed healthcare failing to reach scale is well documented. Less examined is why sophisticated investors with genuine healthcare conviction keep funding ventures that follow the same trajectory. Part of the answer is that standard due diligence captures what is easiest to measure: clinical evidence, market size, team credentials, traction in early accounts. It is weaker at surfacing the structural economic questions that determine whether traction converts to durable revenue. The questions worth adding to any healthcare investment evaluation: What is the procurement pathway in the target market, and has it been navigated before in a comparable context? Not "is procurement a risk" but "who decides, how long does it take, and what has it taken to get comparable products through it?" Where does value accrue economically, and is the pricing model aligned with that? If the answer to where value lands and who is being asked to pay for it are pointing in different directions, someone has a theory for bridging that gap. What is it, and has it been tested? What is the reimbursement dependency, and what happens to the unit economics if reimbursement is delayed by eighteen months? This question kills a significant number of otherwise promising health-tech business models. Ask it early. What does the contract renewal and expansion motion look like at an institutional level? Healthcare contracts are rarely standard SaaS renewals. Expansion into a health system involves new stakeholders, new budget cycles, and often a fresh procurement process. The commercial model needs to account for that cost. These are not questions designed to kill good investments. They are questions that surface whether the economics have been designed, or whether the expectation is that clinical evidence will carry the commercial motion on its own. It rarely does. ## The standard Healthcare is not short of good ideas. It is not short of clinical evidence. What it is consistently short of is the economic architecture that allows good ideas to reach the people they were built for. Designing that architecture is not a phase two problem. It is not something commercial teams figure out after product-market fit. It runs in parallel with clinical development, because the system you are entering has its own logic, and that logic does not pause for your trial results. The founders and investors who understand this do not treat it as a constraint. They treat it as the design brief. Acuvera works with founders, investors, and health-technology companies on the financial sustainability and business-model choices that determine whether innovation reaches scale. The work covers commercial strategy, pricing and reimbursement, partnership structures, and the unit economics of new care models.